Immune Globulin Articles
A new study shows treatment with IVIG shows promise for children and young adults with Down syndrome regression disorder (DSRD).
Italian investigators conducted a trial to assess the safety and efficacy of IVIG in treatment-resistant painful diabetic polyneuropathy (DPN).
A new systematic review and meta-analysis conducted by U.S. and Nepalese collaborators supports the use of IVIG with glucocorticoids compared to IVIG alone.
While intravenous immune globulin (IVIG) therapy is efficacious for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), the lack of biomarkers for disease activity makes the need for ongoing treatment difficult to assess.
Observational studies suggest immune globulin (IG) treatment may reduce the frequency of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.
Sandoz has announced that the citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection became available in the United States starting July 1, 2023.
The U.S. Food and Drug Administration (FDA) has approved Ziextenzo (pegfilgrastim-bmez), the 24th biosimilar approval in the U.S.
Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) at the Immune Deficiency Foundation (IDF) National Conference in June.
A trial was conducted to assess the safety and efficacy of hIVIG (in conjunction with standard care) in adults hospitalized with laboratory-confirmed influenza A or B infection.
The U.S. Patent and Trademark Office has issued a patent to ADMA Biologics for methods of treatment and prevention of S. pneumonia infection.
A team of Dutch investigators enrolled 18 multifocal motor neuropathy (MMN) patients on intravenous immune globulin(IVIG) treatment in a prospective open-label study to evaluate the comparative safety of treatment with 10% human immune globulin whose subcutaneous administration is facilitated with recombinant human hyaluronidase (fSCIG) (HyQvia).